SCM
HZNP

Seamans Capital Management’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Seamans Capital Management’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-69,800
Closed -$1.1M – 81
2014
Q2 		$1.1M Buy
+69,800
New +$996K 1.54% 26

Other funds holding HZNP

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
MRM
Michael R. Murphy $255M AUM 0.87% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Seamans Capital Management's HZNP Position: Q3 2014 in Review

Seamans Capital Management sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q3 2014, closing a stake of 69,800 shares — an estimated $1.1M sold.

Seamans Capital Management first reported a position in HZNP in Q2 2014 and held it in 1 quarter. The position peaked at $1.1M in Q2 2014. 120 funds tracked by Wall St. Rank hold HZNP as of Q3 2014.

  • Seamans Capital Management reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q3 2014 after selling out during the quarter.
  • Seamans Capital Management sold 69,800 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q3 2014, an estimated $1.1M.
  • Seamans Capital Management first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2014 and held it in 1 quarter.
  • Seamans Capital Management's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $1.1M in Q2 2014.
  • 120 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q3 2014.

Based on Seamans Capital Management's 13F filing for Q3 2014, filed 13 Nov 2014.